Paz Ribas
Overview
Explore the profile of Paz Ribas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gonzalez-Calle V, Rodriguez-Otero P, Sureda A, de Arriba F, Reinoso M, Ribas P, et al.
Haematologica
. 2024 Feb;
109(7):2219-2228.
PMID: 38356463
The treatment landscape for multiple myeloma has significantly evolved in the last decade. Notwithstanding, a large proportion of patients continue to relapse and novel combinations continue to be needed. In...
2.
Rodriguez-Otero P, Sirvent M, Gonzalez-Rodriguez A, Lavilla E, Garcia de Coca A, Arguinano J, et al.
Clin Lymphoma Myeloma Leuk
. 2021 Mar;
21(6):413-420.
PMID: 33741302
Introduction: Treatment of relapsed/refractory multiple myeloma (RRMM) is highly challenging, especially for patients with disease refractory to initial therapy, and in particular for disease developing refractoriness to lenalidomide. Indeed, with...
3.
Cejalvo M, Legarda M, Abella E, Cabezudo E, Encinas C, Garcia-Feria A, et al.
Br J Haematol
. 2019 Dec;
190(5):e289-e292.
PMID: 31792926
No abstract available.
4.
Cejalvo M, Ribas P, Rubia J
Expert Opin Drug Saf
. 2017 May;
16(6):753-760.
PMID: 28490215
The overall survival of patients with multiple myeloma (MM) has changed dramatically in the last decade. MM remains an incurable plasma cell disorder but immunotherapy with monoclonal antibodies (MoAbs) has...
5.
Rubia J, Cejalvo M, Ribas P
Leuk Lymphoma
. 2015 Oct;
57(2):258-268.
PMID: 26428053
Infectious complications are an important risk factor for early mortality in patients with multiple myeloma. However, data about the impact and severity of infections in these patients in the era...
6.
Perez R, Duran M, Mayans J, Soler A, Castillo I, Jurado M, et al.
Eur J Haematol
. 2015 Jul;
96(4):417-24.
PMID: 26190662
Therapeutic approaches against multiple myeloma (MM) have largely changed during the past decade. Hematopoietic stem cell transplantation (HSCT) and licensing of immunomodulators and proteasome inhibitors have resulted in better response...
7.
Garcia-Sanz R, Oriol A, Moreno M, Rubia J, Payer A, Hernandez M, et al.
Haematologica
. 2015 Jun;
100(9):1207-13.
PMID: 26069291
This study analyzed the anti-myeloma effect of zoledronic acid monotherapy by investigating patients at the time of asymptomatic biochemical relapse. One hundred patients were randomized to receive either zoledronic acid...
8.
Blanes M, Gonzalez J, Lahuerta J, Ribas P, Lorenzo I, Boluda B, et al.
Leuk Lymphoma
. 2014 May;
56(2):415-9.
PMID: 24828869
A bortezomib-containing regimen followed by high-dose therapy and autologous stem cell transplant (ASCT) is considered the standard of care for front-line therapy in younger patients with newly diagnosed multiple myeloma...
9.
Blanes M, Lahuerta J, Gonzalez J, Ribas P, Solano C, Alegre A, et al.
Biol Blood Marrow Transplant
. 2012 Aug;
19(1):69-74.
PMID: 22897964
Melphalan 200 mg/m(2) (MEL200) is the standard conditioning regimen administered to newly diagnosed patients with multiple myeloma (MM) undergoing autologous stem cell transplantation (ASCT). Few alternatives have been explored in...
10.
Blanes M, Rubia J, Lahuerta J, Gonzalez J, Ribas P, Solano C, et al.
Leuk Lymphoma
. 2009 Feb;
50(2):216-22.
PMID: 19197734
We evaluated the toxicity and outcome of a conditioning regimen comprising intravenous (iv) busulfan (BU) and melphalan (MEL) in 55 patients (median age, 61 years; range, 34-71) with multiple myeloma...